Immune System Key

Company Overview

Snapshot

Founded in February 1992 by Dr. Yoram Devary and Prof. Uziel Sandler, Immune System Key operates with 1-10 employees. The company has raised $3.7 million across 6 funding rounds from 1 investor. In November 2018, Immune System Key received a new US patent for metastatic cancer treatment.

Business overview

Immune System Key (ISK) is a Health Tech & Life Sciences company focused on the discovery and development of treatments for malignant cancers and autoimmune diseases. The company's core product, Nerofe, is based on novel human-secreted peptides designed to inhibit cancer progression. ISK primarily serves the pharmaceutical and biotechnology sectors, targeting patients with acute myeloid leukemia (AML), pancreatic cancer, and triple-negative breast cancer.

Strategic signal

In November 2018, Immune System Key secured a new US patent for metastatic cancer treatment related to its lead compound, Nerofe. This patent signifies a critical validation of the company's intellectual property and therapeutic approach, potentially enhancing its market position and attractiveness for future partnerships or investment in the oncology drug development landscape.

Company Intelligence Q&A

When was Immune System Key founded?

Immune System Key was founded in February 1992 by Dr. Yoram Devary and Prof. Uziel Sandler.

What is Immune System Key's primary focus in drug development?

Immune System Key is focused on the discovery and development of treatments for malignant cancers and autoimmune diseases, specifically targeting acute myeloid leukemia (AML), pancreatic cancer, and triple-negative breast cancer.

What is Nerofe and its significance?

Nerofe is Immune System Key's lead compound, a novel human-secreted peptide designed to inhibit cancer progression by inducing anti-angiogenic effects and activating anticancer immune responses. Nerofe has also been granted orphan status by the FDA for the treatment of AML.

Has Immune System Key received any patents for its treatments?

Yes, in November 2018, Immune System Key received a new US patent for metastatic cancer treatment related to its Nerofe compound.

What was a key development for Immune System Key in April 2019?

In April 2019, Prof. Marc E. Lippman, a renowned breast cancer expert, joined Immune System Key.